Literature DB >> 33983432

Cluster analysis reveals 3 main patterns of behavior towards SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases.

Renaud Felten1, Maxime Dubois1, Manuel Francisco Ugarte-Gil2, Aurore Chaudier1, Lou Kawka1, Hugo Bergier1, Charlotte Costecalde1, Luc Pijnenburg1, Jérémy Fort1, Emmanuel Chatelus1, Christelle Sordet1, Rose-Marie Javier1, Jacques-Eric Gottenberg1, Jean Sibilia1, Yurilis J Fuentes-Silva3, Laurent Arnaud1.   

Abstract

INTRODUCTION: Given the COVID19 pandemic, it is crucial to understand the underlying behavioral determinants of SARS-CoV-2 vaccine hesitancy in patients with autoimmune or inflammatory rheumatic diseases AIIRD. We aimed to analyze patterns of behaviors regarding SARS-CoV-2 vaccination in AIIRD patients, as a mean to identify pragmatic actions to increase vaccine coverage in this population.
METHODS: Data of 1258 AIIRD patients were analyzed using univariate and multivariate logistic regression models, to identify variables associated independently with the willingness to get vaccinated against SARS-CoV-2. Subsets of patients showing similar behaviors towards SARS-CoV-2 vaccination were characterized using cluster analysis.
RESULTS: Hierarchical cluster analysis identified 3 distinct clusters of AIIRD patients. Three predominant patients' behavior towards SARS-COV-2 vaccination: 'voluntary', 'hesitant' and 'suspicious' were identified. While vaccine willingness was significantly different across the 3 clusters p< 0.0001, there was no difference regarding the fear to get COVID-19 p= 0.11, the presence of co-morbidities p= 0.23, the use of glucocorticoids p= 0.21 or the immunocompromised status p= 0.63. However, patients from cluster #3 'suspicious' were significantly more concerned about vaccination, the use of a new vaccine technology, the lack of hindsight regarding COVID vaccination and potential financial links with pharmaceutical companies p< 0.0001 in all than in the other 2 clusters. DISCUSSION: Importantly, the differences between patients' behaviors are not related to the fear of getting COVID-19 or to any state of frailty, but point out to specific concerns about vaccination. This study may serve as a basis for improved communication, to increase COVID-19 vaccine coverage in AIIRD patients.
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; autoimmune diseases; behavior; cluster analysis; inflammatory rheumatic diseases; vaccination

Year:  2021        PMID: 33983432      PMCID: PMC8194533          DOI: 10.1093/rheumatology/keab432

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  7 in total

1.  COVID-19 vaccine hesitancy among Mexican outpatients with rheumatic diseases.

Authors:  Guillermo Guaracha-Basáñez; Irazú Contreras-Yáñez; Everardo Álvarez-Hernández; Carla Marina Román-Montes; Graciela Meza-López Y Olguín; María José Morales-Graciano; Salvador Saúl Valverde-Hernández; Ingris Peláez-Ballestas; Virginia Pascual-Ramos
Journal:  Hum Vaccin Immunother       Date:  2021-12-02       Impact factor: 3.452

2.  Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries.

Authors:  Lina El Kibbi; Mona Metawee; Ihsane Hmamouchi; Nizar Abdulateef; Hussein Halabi; Mervat Eissa; Manal El Rakawi; Basel Masri; Fatemah Abutiban; Wafa Hamdi; Asal Adnan; Antonella Abi Najm; Renaud Felten; Laurent Arnaud; Nelly Ziadé
Journal:  Lancet Rheumatol       Date:  2021-12-13

3.  Factors associated to COVID-19 vaccine acceptance in Mexican patients with rheumatic diseases: A cross-sectional and multicenter study.

Authors:  Guillermo Arturo Guaracha-Basañez; Irazú Contreras-Yáñez; Everardo Álvarez-Hernández; Greta Reyes-Cordero; Diana Elsa Flores-Alvarado; Susana Aidée González-Chávez; Dionicio Ángel Galarza-Delgado; Perla Rocío Martínez-Leyva; José Francisco Moctezuma-Ríos; Conrado García-García; Gabriel Medrano-Ramírez; Alfonso Gastelum-Strozzi; César Pacheco-Tena; Ingris Peláez-Ballestas; Virginia Pascual-Ramos
Journal:  Hum Vaccin Immunother       Date:  2022-04-07       Impact factor: 4.526

4.  Barriers and facilitators to vaccination uptake against COVID-19, influenza, and pneumococcal pneumonia in immunosuppressed adults with immune-mediated inflammatory diseases: A qualitative interview study during the COVID-19 pandemic.

Authors:  Amy Fuller; Jennie Hancox; Kavita Vedhara; Tim Card; Christian Mallen; Jonathan S Nguyen Van-Tam; Abhishek Abhishek
Journal:  PLoS One       Date:  2022-09-09       Impact factor: 3.752

5.  How to optimize recruitment strategies of patients with rheumatic and musculoskeletal diseases for online surveys: experience from an international study.

Authors:  Renaud Felten; Laurent Arnaud; Ihsane Hmamouchi; Antonella Abi Najm; Lina El Kibbi; Mona Metawee; Hussein Halabi; Nizar Abdulateef; Mervat Eissa; Manal El Rakawi; Basel Masri; Fatma Boutaiban; Wafa Hamdi; Asal Adnan; Nelly Ziadé
Journal:  Rheumatol Int       Date:  2022-09-30       Impact factor: 3.580

6.  Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study.

Authors:  Renaud Felten; Lou Kawka; Maxime Dubois; Manuel F Ugarte-Gil; Yurilis Fuentes-Silva; Matteo Piga; Laurent Arnaud
Journal:  Lancet Rheumatol       Date:  2021-07-21

7.  Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination.

Authors:  Jie Lu; Yuwei He; Robert Terkeltaub; Mingshu Sun; Zijing Ran; Xinmiao Xu; Can Wang; Xinde Li; Shuhui Hu; Xiaomei Xue; Fei Yan; Hui Zhang; Huiyong Yin; Yongyong Shi; Nicola Dalbeth; Changgui Li
Journal:  Ann Rheum Dis       Date:  2022-03-11       Impact factor: 27.973

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.